Skip to main content
Log in

Tenoten in the Therapy of Patients with Moderate Cognitive Impairment

  • Ultralow Doses
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Tenoten is a new anxiolytic and antidepressant based on antibodies to brain-specifi c protein S-100B. Experimental studies demonstrated the effect of tenoten on mechanisms of neuronal plasticity and manifestations of higher nervous activity. Tenoten is clinically comparable with amitryptiline, sertraline, and phenazepam, but does not produce potent sedative relaxation effect typical of these drugs. The study demonstrated considerable improvement of the control over brain frontal compartment effector functions. Tenoten is recommended not only at the stage of moderate cognitive impairment, but also in manifest cerebrovascular pathologies characterized by pronounced impairment of the regulatory functions of the frontal compartments of the brain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. N. A. Bokhan, A. F. Abolonin, E. N. Krylov, et al., Byull. Exp. Biol. Med., Suppl. 2, 199-204 (2003).

    Google Scholar 

  2. Kh. L. Gainutdinov, V. V. Andrianov, N. A. Beregovoi, et al., Zh. Evolut. Biokhim. Fiziol., 42, No. 3, 225-230 (2006).

    Google Scholar 

  3. A. G. Gofman, I. N. Pyatnitskaya, Yu. V. Valentik, et al., Byull. Exp. Biol. Med., Suppl. 2, 194-208 (2003).

    Google Scholar 

  4. L. V. Loskutova, M. B. Shtark, and O. I. Epshtein, Ibid., pp. 24-26.

  5. I. F. Pavlov, Ibid., 143, No. 6, 628-630 (2007).

    Google Scholar 

  6. T. M. Pankova, M. V. Starostina, M. B. Shtark, and O. I. Epshtein, Ibid, 144, No. 9, pp. 260-263.

  7. O. I. Epshtein, M. B. Shtark, A. Kh. Timoshenko, et al., Ibid., 143, No. 5, pp. 490-493.

  8. O. I. Epshtein, O. V. Vorob’eva, L. N. Grinkevich, et al., Ibid, 144, No. 9, pp. 293-296.

  9. N. N. Yakhno, V. V. Zakharov, and A. B. Lokshina, Zh. Nevrol. Psikhiatr., 105, No. 2, 13-17 (2005).

    Google Scholar 

  10. B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, Neurology, 55, No. 11, 1621-1626 (2000).

    CAS  PubMed  Google Scholar 

  11. O. I. Epshtein, I. F. Pavlov, and M. B. Shtark, Evid. Based Complement Alternal. Med., 3, No. 4, 541-544 (2006).

    Article  Google Scholar 

  12. M. D. Lezak, Neuropsychological Assessment, New York (1983).

  13. G. P. Wolf-Klein, F. A. Silverstone, A. P. Levy, and M. S. Brod, J. Am. Geriatr. Soc., 37, No. 8, 730-734 (1989).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. A. Duma.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 103-106, August, 2009

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duma, S.A., Shishkin, S.V. Tenoten in the Therapy of Patients with Moderate Cognitive Impairment. Bull Exp Biol Med 148, 353 (2009). https://doi.org/10.1007/s10517-009-0679-8

Download citation

  • Received:

  • Published:

  • DOI: https://doi.org/10.1007/s10517-009-0679-8

Key Words

Navigation